Isatuximab-Irfc

Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.

The FDA approved isatuximab-irfc in combination with bortezomib, lenalidomide and dexamethasone for treatment of certain adults with multiple myeloma.

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma.

CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.

Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.

The addition of isatuximab-irfc to carfilzomib and dexamethasone conferred a durable PFS benefit to patients with relapsed multiple myeloma, according to updated results of the randomized phase 3 IKEMA trial.

Myeloma Awareness Month is observed in March.

The addition of isatuximab to a standard three-drug induction regimen improved outcomes for certain patients with multiple myeloma, according to randomized phase 3 study results presented at ASH Annual Meeting and Exposition.